Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Lessened by APG Asset Management US Inc.

APG Asset Management US Inc. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,240 shares of the biopharmaceutical company’s stock after selling 267 shares during the quarter. APG Asset Management US Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,596,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Integrated Wealth Concepts LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 40.1% during the third quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock valued at $786,000 after purchasing an additional 214 shares during the last quarter. EP Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 16.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,467 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 209 shares during the last quarter. MML Investors Services LLC grew its position in Regeneron Pharmaceuticals by 13.9% in the third quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company’s stock worth $5,587,000 after acquiring an additional 648 shares in the last quarter. M&T Bank Corp increased its position in Regeneron Pharmaceuticals by 4.3% during the third quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company’s stock worth $5,761,000 after buying an additional 224 shares during the last quarter. Finally, Vestcor Inc raised its stake in shares of Regeneron Pharmaceuticals by 3.1% in the 3rd quarter. Vestcor Inc now owns 21,590 shares of the biopharmaceutical company’s stock valued at $22,696,000 after acquiring an additional 654 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.8 %

Shares of Regeneron Pharmaceuticals stock opened at $556.81 on Wednesday. The firm’s 50 day moving average price is $669.26 and its 200-day moving average price is $766.90. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $536.23 and a 52-week high of $1,211.20. The company has a market cap of $60.87 billion, a P/E ratio of 14.55, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $11.86 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on REGN shares. TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Bank of America reiterated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.